Article
Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Feb 2014
Tural Deniz, Batur Sebnem, Erdamar Sibel, Akar Emre, Kepil Nuray, Mandel Nil Molinas, Serdengeçti Süheyla
Abstract excerpt
We investigated predictive values of BRAF, PI3K and PTEN in cetuximab responses in KRAS wild-type (+) chemotherapy refractory, metastatic colorectal cancer (CRC) patients. Primary tumour tissues of 41 KRAS wild-type mCRC patients receiving cetuximab-based chemotherapy were investigated for PI3K, PTEN, KRAS and BRAF mutations. Progression-free survival (PFS) and overall survival (OS) periods were calculated with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.